AIMS: To determine levels of expression of Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) in benign and malignant tissues harbouring EBV in relation to EBNA1 promoter usage. METHODS: Expression of EBNA1 was investigated by means of immunohistochemistry using a mixture of two EBNA1 specific monoclonal antibodies, 1H4-1 and 2B4-1. The presence of EBV was detected by EBER1/2 RNA in situ hybridisation. Detection of promoter specific EBNA1 transcripts was by RT-PCR analysis. RESULTS: EBNA1 positive cells were detected in all 20 EBV associated B cell lymphomas, 18 of which had arisen in immunocompromised patients; in eight of nine EBV associated T cell lymphomas; in 11 of 27 EBV positive cases of Hodgkin's disease; and in reactive lymphoid tissue harbouring EBV, including four cases of infectious mononucleosis. A diffuse EBNA1 staining pattern was observed in most of the EBV associated B cell lymphomas and was comparable with the EBER1/2 staining pattern. In the T cell lymphomas the number of EBNA1 positive cells was usually considerably less than the number of EBER1/2 positive ones. RT-PCR analysis revealed that in tumours with restricted EBNA1 expression-that is, T cell lymphomas and Hodgkin's disease lesions, EBNA1 transcripts were usually generated only by the F/Q promoter, whereas in B cell lymphomas EBNA1 transcripts were usually generated by both the C/W and F/Q promoters. CONCLUSIONS: EBNA1 is expressed in all types of tissue harbouring EBV, but the level of expression varies greatly. This may be the result of differential promoter usage.
AIMS: To determine levels of expression of Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) in benign and malignant tissues harbouring EBV in relation to EBNA1 promoter usage. METHODS: Expression of EBNA1 was investigated by means of immunohistochemistry using a mixture of two EBNA1 specific monoclonal antibodies, 1H4-1 and 2B4-1. The presence of EBV was detected by EBER1/2 RNA in situ hybridisation. Detection of promoter specific EBNA1 transcripts was by RT-PCR analysis. RESULTS:EBNA1 positive cells were detected in all 20 EBV associated B cell lymphomas, 18 of which had arisen in immunocompromised patients; in eight of nine EBV associated T cell lymphomas; in 11 of 27 EBV positive cases of Hodgkin's disease; and in reactive lymphoid tissue harbouring EBV, including four cases of infectious mononucleosis. A diffuse EBNA1 staining pattern was observed in most of the EBV associated B cell lymphomas and was comparable with the EBER1/2 staining pattern. In the T cell lymphomas the number of EBNA1 positive cells was usually considerably less than the number of EBER1/2 positive ones. RT-PCR analysis revealed that in tumours with restricted EBNA1 expression-that is, T cell lymphomas and Hodgkin's disease lesions, EBNA1 transcripts were usually generated only by the F/Q promoter, whereas in B cell lymphomasEBNA1 transcripts were usually generated by both the C/W and F/Q promoters. CONCLUSIONS:EBNA1 is expressed in all types of tissue harbouring EBV, but the level of expression varies greatly. This may be the result of differential promoter usage.
Authors: J Sample; L Brooks; C Sample; L Young; M Rowe; C Gregory; A Rickinson; E Kieff Journal: Proc Natl Acad Sci U S A Date: 1991-07-15 Impact factor: 11.205
Authors: H Herbst; F Dallenbach; M Hummel; G Niedobitek; S Pileri; N Müller-Lantzsch; H Stein Journal: Proc Natl Acad Sci U S A Date: 1991-06-01 Impact factor: 11.205
Authors: J W Gratama; M M Zutter; J Minarovits; M A Oosterveer; E D Thomas; G Klein; I Ernberg Journal: Int J Cancer Date: 1991-01-21 Impact factor: 7.396
Authors: A G Stansfeld; J Diebold; H Noel; Y Kapanci; F Rilke; G Kelényi; C Sundstrom; K Lennert; J A van Unnik; O Mioduszewska Journal: Lancet Date: 1988-02-06 Impact factor: 79.321
Authors: S J Hamilton-Dutoit; G Pallesen; M B Franzmann; J Karkov; F Black; P Skinhøj; C Pedersen Journal: Am J Pathol Date: 1991-01 Impact factor: 4.307
Authors: G Frizzera; D W Hanto; K J Gajl-Peczalska; J Rosai; R W McKenna; R K Sibley; K P Holahan; L L Lindquist Journal: Cancer Res Date: 1981-11 Impact factor: 12.701
Authors: D Kube; M Vockerodt; O Weber; K Hell; J Wolf; B Haier; F A Grässer; N Müller-Lantzsch; E Kieff; V Diehl; H Tesch Journal: J Virol Date: 1999-02 Impact factor: 5.103
Authors: Eduardo L V Silveira; Mark H Fogg; Rachel M Leskowitz; Hildegund C Ertl; Roger W Wiseman; David H O'Connor; Paul Lieberman; Fred Wang; Francois Villinger Journal: J Virol Date: 2013-10-02 Impact factor: 5.103
Authors: Joanna B Wilson; Evelyne Manet; Henri Gruffat; Pierre Busson; Marc Blondel; Robin Fahraeus Journal: Cancers (Basel) Date: 2018-04-06 Impact factor: 6.639